Analyzing Histogen (NASDAQ:HSTO) & Indaptus Therapeutics (NASDAQ:INDP)

Indaptus Therapeutics (NASDAQ:INDP) and Histogen (NASDAQ:HSTO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Indaptus Therapeutics and Histogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-177.27%	-141.06%
Histogen	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and price targets for Indaptus Therapeutics and Histogen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	0	0	2	0	3.00
Histogen	0	0	0	0	0.00

Indaptus Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 1,728.35%. Given Indaptus Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Indaptus Therapeutics is more favorable than Histogen.

Valuation and Earnings

This table compares Indaptus Therapeutics and Histogen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$15.42 million	($1.62)	-0.29
Histogen	$19,000.00	6.52	-$10.62 million	($2.81)	-0.01

Histogen has higher revenue and earnings than Indaptus Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Histogen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 29.5% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 3.3% of Histogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Indaptus Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Histogen has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Summary

Indaptus Therapeutics beats Histogen on 7 of the 12 factors compared between the two stocks.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

About Histogen

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.